NASDAQ · IMDX
Healthcare · Biotechnology
$4.01
Up+$0.11 (+2.74%)
Updated Sep 4, 2026, 12:28 AM
SID Score
2.7/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 20 trading sessions · Daily adjusted prices
IMDX closed at $4.01 after 20 trading sessions, down 16.46% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 2, 2026 | $3.81 | $4.04 | $3.71 | $4.01 | 80.82K |
| Sep 1, 2026 | $3.86 | $3.99 | $3.74 | $3.84 | 128.12K |
| Aug 31, 2026 | $4.10 | $4.115 | $3.88 | $3.92 | 102.4K |
| Aug 28, 2026 | $4.245 | $4.48 | $4.10 | $4.13 | 81.03K |
| Aug 27, 2026 | $4.27 | $4.32 | $4.23 | $4.29 | 36.36K |
| Aug 26, 2026 | $4.41 | $4.43 | $4.29 | $4.30 | 44.54K |
| Aug 25, 2026 | $4.35 | $4.54 | $4.35 | $4.44 | 155.94K |
| Aug 24, 2026 | $4.37 | $4.4626 | $4.20 | $4.32 | 83.11K |
| Aug 21, 2026 | $4.40 | $4.455 | $4.31 | $4.34 | 38.69K |
| Aug 20, 2026 | $4.36 | $4.435 | $4.20 | $4.30 | 112.16K |
| Aug 19, 2026 | $4.29 | $4.50 | $4.25 | $4.38 | 146.93K |
| Aug 18, 2026 | $4.22 | $4.35 | $4.09 | $4.28 | 318.06K |
| Aug 17, 2026 | $4.29 | $4.365 | $4.01 | $4.27 | 97.07K |
| Aug 14, 2026 | $3.76 | $4.36 | $3.76 | $4.32 | 331.69K |
| Aug 13, 2026 | $4.47 | $4.485 | $3.54 | $3.71 | 1.16M |
| Aug 12, 2026 | $4.48 | $4.50 | $4.15 | $4.50 | 279.65K |
| Aug 11, 2026 | $4.60 | $4.8808 | $4.20 | $4.43 | 522.32K |
| Aug 10, 2026 | $4.85 | $4.93 | $4.76 | $4.77 | 83.02K |
| Aug 7, 2026 | $4.85 | $4.935 | $4.70 | $4.83 | 41.98K |
| Aug 6, 2026 | $4.92 | $5.06 | $4.66 | $4.80 | 137.49K |
The latest Smart Investors Daily articles mentioning IMDX.
IMDX research
Company profile and research snapshot.
Insight Molecular Diagnostics Inc is a pioneering diagnostics technology company whose mission is to democratize access to novel molecular diagnostic testing to improve patient outcomes. The Company's flagship technology quantifies a molecular biomarker known as donor-derived cell-free DNA (dd-cfDNA). It is also in the process of rebranding its RUO test kit, GraftAssure, as GraftAssureIQ, and rebranding its future in-vitro diagnostic (IVD) test kit as GraftAssureDx.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 24, 2026 | LUCID CAPITAL MARKETS | Buy | — |
| Aug 18, 2026 | Needham | Buy | — |
| Feb 17, 2026 | Lake Street | Buy | — |
| Nov 11, 2025 | Needham | Buy | — |
| Aug 18, 2025 | Needham | Buy | — |
No generated briefing is available yet.
Benzinga · Aug 24, 2026
LUCID CAPITAL MARKETS analyst Alex Nowark initiates coverage on Insight Molecular (NASDAQ:IMDX) with a Buy rating and announces Price Target of $8.
Benzinga · Aug 24, 2026
Insight Molecular (NASDAQ:IMDX) released second-quarter financial results and hosted an earnings call on Monday. Read the complete transcript below. Benzinga APIs provide real-time access to earnings call transcripts
Benzinga · Aug 18, 2026
Needham analyst Mike Matson reiterates Insight Molecular (NASDAQ:IMDX) with a Buy and maintains $9 price target.
SeekingAlpha · Aug 17, 2026
Insight Molecular Diagnostics Inc. (IMDX) Discusses Advances in Heart Transplant Rejection Testing and Evolution of Diagnostic Methods August 17, 2026 11:00...
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning IMDX.
